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Abstract 
Heterotopic ossification (HO) is a debilitating condition defined by the de novo development 
of bone within non-osseous soft tissues, and can be either hereditary or acquired.  The 
hereditary condition, fibrodysplasia ossificans progressiva (FOP) is rare but life threatening.  
Acquired HO is more common and results from a severe trauma that produces an 
environment conducive for the formation of ectopic endochondral bone.  Despite continued 
efforts to identify the cellular and molecular events that lead to HO, the mechanisms of 
pathogenesis remain elusive.  It has been proposed that the formation of ectopic bone requires 
an osteochondrogenic cell type, the presence of inductive agent(s), and a permissive local 
environment.  To date several lineage-tracing studies have identified potential contributory 
populations.  However, difficulties identifying cells in vivo based on the limitations of 
phenotypic markers, along with the absence of established in vitro HO models have made the 
results difficult to interpret.  The purpose of this review is to critically evaluate current 
literature within the field in an attempt identify the cellular mechanisms required for ectopic 
bone formation.  The major aim is to collate all current data on cell populations that have 
been shown to possess an osteochondrogenic potential and identify environmental conditions 
that may contribute to a permissive local environment.  This review outlines the pathology of 
endochondral ossification, which is important for the development of potential HO therapies 
and to further our understanding of the mechanisms governing bone formation. 
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Heterotopic Ossification  
Heterotopic ossification (HO) is defined by the de novo formation of lamellar bone within 
non-osseous soft tissues.  Tissue formed through the process of HO is intriguing since it is 
composed of endochondral bone, which contains a central canal filled with bone marrow [1].  
This distinguishes the process of HO from other pathological conditions characterised by the 
deposition of ectopic mineral within soft tissues, such as progressive osseous heteroplasia 
(lacks endochondral ossification) and dystrophic calcification (associated with the 
development of kidney stones and lacking the presence of bone marrow) [2,3].  The 
development of acquired HO is predominantly associated with severe trauma, particularly to 
muscle or neuronal tissues, such as traumatic brain injury, spinal cord injury, joint 
arthroplasty, severe burns or combat blast wounds and amputations [4,5].  In fact, of the 80% 
of war victims who suffer major extremity trauma during combat injury, approximately 64% 
of these patients go on to develop some degree of HO [6,7].  Aside from physical trauma, HO 
is also associated with the hereditary condition fibrodysplasia ossificans progressiva (FOP).  
However, this hereditary form of HO is rare (less than one per million of the population), 
comparatively well understood, and potentially less pathologically complex when compared 
with acquired HO.  Both hereditary and acquired HO are debilitating conditions that can lead 
to the atrophy of skin and soft tissue breakdown throughout the residual limb, severe pain, 
nerve entrapment and impaired joint movement. Current treatments are invasive (surgical 
removal) or non-specific (radiation therapy or non-steroidal anti-inflammatory drugs), with 
the likelihood of HO recurrence potentially reaching levels of 25% [6,8].  Therefore, the need 
to understand the complex pathological mechanisms underlying HO is of great importance if 
effective therapies are to be devised.  This review will provide a clinical and biological 
evaluation of HO, and provide a current perspective of the cellular and molecular mechanism 
leading to ectopic bone formation. 
Clinical Problems  
Patients with HO experience a wide range of problems due to the mechanical effects of hard 
tissue formation in extra-skeletal sites. These include pain, loss of joint mobility, skin 
ulceration, overlying skin graft failure, muscle and neurovascular entrapment, and prosthetic 
limb fitting difficulties [9].  Clinically, HO first presents with pain and swelling in the 
affected limb [10]. This can cause difficulty with diagnosis as the symptoms overlap with 
infection and deep vein thrombosis, which are also common diagnoses in these patients. 
Nerve blocks or ablations, and excisions form the mainstay of surgical treatments [5]. Rest, 
analgesia, non-steroidal anti-inflammatory drugs (NSAIDs), radiotherapy, bisphosphonates, 
and physiotherapy are common non-surgical approaches [5]. NSAIDs are used widely to 
cover a variety of situations where patients are at risk of developing HO, and reports 
concerning the efficacy of these drugs vary [11]. There is evidence that, in addition to their 
normal side effect profile, NSAIDs increase the risk of non-union after acetabular fixation 
and inhibit bone remodelling [12,13]. Additionally, NSAID administration carries the risk of 
gastric irritation, occasionally preventing (20-37%) patients from completing treatment [14].  
Single dose radiotherapy is widely used and there is persuasive clinical evidence 
demonstrating its effectiveness as a HO prophylactic following surgery [15-17]. Furthermore, 
radiotherapy and NSAIDs may be given in combination pre- or post-operatively for high-risk 
patients [18]. This type of combination treatment has perhaps proven most effective for 
preventing HO recurrence following surgery (e.g. the excision of ectopic bone) [18]. 
However, radiotherapy is by no means ideal since it carries a number of potential risks such 
as malignancy, genetic mutations, and gonadal effects [19,20]. Bisphosphonate use remains 
controversial after a Cochrane review [21] failed to find conclusive evidence of efficacy. 
Furthermore, these drugs act to delay the onset of HO rather than prevent it. A second 
Cochrane review [22] investigating the use of passive movement physiotherapy in a 
heterogeneous group of patients (including traumatic brain injury and spinal cord injury 
patients at risk of HO) concluded that there is insufficient evidence to show whether or not 
this therapy is effective. It is our view that a better understanding of the cellular and 
molecular pathology underlying HO is required to develop improved prophylactic treatments.   
Pathogenesis 
Current evidence suggests that the formation of ectopic bone in vivo requires three primary 
conditions: (1) a cell type capable of osteogenic differentiation, (2) the presence of inductive 
agents, (3) a permissive local environment [23].  However, despite continued efforts to 
identify the cellular and molecular events leading to HO, the mechanisms of pathogenesis 
continue to remain elusive.  To date many contributory biological factors have been 
implicated in the etiology (see diagram 1), including the bone morphogenetic proteins 
(BMPs), inflammation, prostaglandin E2, hypercalcemia, hypoxia, abnormal nerve activity, 
immobilization and dysregulation of hormones [1,24].  However, in addition to the biological 
contribution, HO is also associated with a change in local biomechanics, as can be observed 
following reparative surgeries, such as cervical total disc replacement, where resulting 
changes in height of the functional segmental unit or increases in range of motion may 
influence the formation of HO [25].  At the onset of acquired HO an injurious stimulus 
produces an inflammatory environment conducive to the formation of endochondral bone 
[26].  This may be accomplished through the local signalling and differentiation of resident 
cells such as myoblasts or satellite cells within muscle, or through the recruitment of systemic 
cell types, such as circulating osteoblast progenitors, pericytes, or vascular endothelial cells, 
that may act either directly or indirectly to promote endochondral ossification.  Therefore 
cells actively involved in the development of HO would have to possess either a residual 
osteochondrogenic potential or acquire this capacity during the tissues response to injury (i.e. 
cross-differentiation).  Currently, the identity of these cells remains controversial, with 
previous reports identifying a large number of potential candidates that may contribute to the 
fibroproliferative and osteochondrogenic phases of HO.  The focus of this review will be to 
provide a critical analysis of current literature within the field in an attempt to elucidate 
candidate cell populations and identify local and systemic factors leading to acquired HO. 
 
 
Fig. 1 Hypothetical mechanism for the pathological changes associated with the development of HO following 
trauma. Tissue damage leads to the infiltration of immunological cells (monocytes, neutrophils and leukocytes) 
through the local vasculature. Resulting fibro-proliferation of an as yet unknown cell population is accompanied 
by hypoxia and the generation of brown adipose tissue at the site of damage. The presence of adipose tissue is 
hypothesised to lower the local oxygen tension leading to the establishment of a chondrogenic environment. 
Neovascularisation accompanies chondrogenesis and provides an avenue through which systemic cell types 
(endothelial cells, pericytes etc.) may enter the injury site, and potentially contributed to osteochondrogenic 
differentiation. A subsequent increase in local oxygen tension promotes chondrocyte maturation and 
hypertrophy. The collagenous matrix deposited by these cells is then remodelled and ossified to form 
endochondral bone. 
 
Cellular Origins  
Mesoderm 
Mesenchymal Stem Cells 
The fact that HO leads to the formation of cartilage, which is subsequently remodelled to 
form lamellar bone has led a number of researchers to postulate a role for mesenchymal stem 
cells (MSCs) in the pathogenesis.  MSCs first isolated by Friedenstein et al. (1987) were 
initially termed bone marrow-derived osteogenic stem cells due to their capacity to form 
cartilage and bone in vitro [27].  MSCs have frequently been shown to form endochondral 
bone when cultured under appropriate conditions (e.g. under hypoxia and/or in the presence 
of TGF-β) [28,29].  Furthermore, in some instances the application of MSCs in vivo 
following an initial period of in vitro chondrogenic differentiation has led to the formation of 
endochondral bone that contained a central bone marrow cavity [30].  Bone marrow stromal 
cells are still considered to be the primary source of all osteoprogenitors found throughout the 
body, and lineage-tracing studies have indicated that intravenously transplanted bone marrow 
cells migrate to and settle in skeletal muscle [31].  However, controversially, few of these 
cells have been shown to migrate to muscle following injury, thereby drawing in to question 
their potential contribution to HO [32]. This suggests that the regenerative response to trauma 
is mounted primarily by stem/progenitor cells located at the site of damage, such as muscle 
precursors.  
New evidence suggests that the focus may need to be shifted from migrating bone marrow 
stromal cells to other available sources of MSCs, such as resident stem/progenitor cells 
located in the damaged tissue.  A clinical study that isolated muscle-derived MSC-like cells 
from trauma patients that had developed HO and compared them with MSCs from trauma 
patients lacking HO and uninjured controls showed for the first time that patients with HO 
had significantly more progenitor cells committed to the osteogenic lineage than traumatised 
non-HO patients [33].  Further investigation indicated that these mesenchymal progenitor 
cells (MPCs) had a comparable osteogenic profile to bone marrow-derived MSCs that had 
been exposed to osteogenic induction medium [34].  However, these cells were thought to be 
incapable of terminal osteogenic differentiation, and as such potentially contribute only in 
part, or only to the initial stages of ectopic bone formation.  Interestingly, the number of 
MSC-like cells isolated from non-HO trauma patients was significantly increased relative to 
uninjured patients but these cells did not contribute to ectopic bone formation [35].  This 
suggests that a threshold must be surpassed before trauma induces progenitor cells to become 
osteogenic.  This threshold may be related to several subsequent events associated with tissue 
damage such as the size of the immunological response, the degree of vascular damage 
incurred, and/or the resulting local oxygen tension following injury.  It may also be 
hypothesised that a certain concentration of chemokines must be present in order to signal the 
recruitment of resident or circulating stem cells, and that this is related to the severity of 
trauma [36].  The need for further work to characterise these cells comprehensively is now of 
great importance if the true identity of this mesenchymal population and its role in HO is to 
be elucidated. 
Evidence implying a role for mesenchymal stem/progenitor cells in HO is related to the 
known age-dependent effects of these cells in vivo.  Recent evidence has shown that the 
development of HO following burn injury may be reduced in older subjects [37].  This is 
significant given that it has been documented for several years that the availability and 
functional activity of MSCs may be reduced with increasing age or passage [38].  This 
appears to be particularly true for bone marrow-derived mesenchymal stem cells (BMSCs), 
with these cells presenting a decreased level of proliferation and differentiation in older 
subjects [39].  Furthermore, when the angiogenic potential of MSCs was investigated in older 
subjects the resulting data demonstrated a reduced capacity for adipose-derived stem cells 
(ADSCs) to form capillary-like networks when compared with ADSCs isolated from younger 
subjects [40].  A MSCs capacity for vascularisation can be improved following hypoxic pre-
conditioning [41].  This is significant given that low oxygen tension can result as a 
consequence of soft-tissue injury, and may implicate MSCs in ectopic bone formation (see 
Diagram 1).  Hypoxia at the site of injury has been hypothesised to result from the formation 
of brown adipocytes within the damage site due to the action of local and systemic factors 
such as BMPs [42].  Currently, no evidence exists to identify the origin of adipose tissue at 
the site of tissue damage.  However, MSCs are defined as multipotent cells capable of 
adipogenic differentiation, and, as such, their contribution to brown adipose tissue formation 
during the early stages of HO cannot be ruled out.  Brown adipocytes formed at the onset of 
HO have been shown to express vascular endothelial growth factors, concurrent with 
endothelial progenitor proliferation [43].  Consequently, the presence of brown adipocytes 
within the lesion reduces the oxygen tension in the adjacent tissue, due to oxidative 
metabolism [42]. The presence of hypoxic stress is a requirement for MSC chondrogenesis, 
which can lead to cell hypertrophy and ossification [42].  MSCs may also contribute to 
chondrocyte hypertrophy and the progression of HO via their immunomodulatory effects, 
primarily through the production of anti-inflammatory cytokines and nitric oxide (NO) [44].  
The production of NO by MSCs has been shown to impair T cell responsiveness following 
injury, thereby modulating the overall immune response [45].  Interestingly, nitric oxide is 
also known to contribute to chondrocyte hypertrophy, which may implicate MSCs and their 
immunomodulatory effects in the development of HO.   
Myoblasts 
A myoblast is a proliferative progenitor cell that differentiates to form mature muscle. These 
cells fuse and align to form multinucleated primary myofibres. Previous studies have shown 
that skeletal muscle contains populations of osteoprogenitor cells, with ectopic bone 
formation being achieved experimentally using solubilised factors obtained from bone [46-
48].  Evidence of an osteogenic capacity has also been recorded for both rat (L6 cells) and 
mouse (C2C12 cells) skeletal muscle myoblasts following transfection with osteogenic 
inducers, such as BMPs [49,50].  Co-culture of C2C12 mouse myoblasts with MSCs has been 
shown to produce a pro-osteogenic environment, as determined by an increase in the 
expression of the primary osteogenic regulator Runx2 [51].  A study by Mu and Li (2010) 
identified TGF-β as a factor capable of inducing myoblast reversion to a multipotent cell type 
[52].  This is interesting given that several TGF-β isoforms have been identified in both 
immature and mature ectopic ossifications of HO patients [53].  The study by Mu and Li 
(2010) showed that incubation of primary myoblasts or C2C12 immortalised myoblasts with 
a transient and small concentration of TGF-β can lead to the expression of more primitive 
markers, Pax7 and Sca-1 [52].  However, in the aforementioned study the authors identify the 
expression of Pax7 and Sca-1 as an indication of reversion to an MSC phenotype, although 
Pax7 is more commonly used as an indicator of satellite cell phenotype, and Sca-1 has also 
been identified as a marker of muscle cell progenitors [54].  Therefore, it may be more likely 
that the presence of inflammatory factors such as TGF-β could lead to a reversion of 
myoblasts to an earlier muscle progenitor/satellite cell type, which may possess an 
osteochondrogenic potential.  Current, in vivo cell tracking studies aiming to define the 
contribution of skeletal muscle cells to HO have yielded some conflicting results.  Liu et al. 
(2012) found that MyoD-Cre+ cells contributed to the formation of ectopic bone when 
induced by the intramuscular delivery of BMP-7 [55].  MyoD is recognised as the master 
regulatory gene for myogenic differentiation in much the same way as Runx2 and PPARγ are 
essential for osteogenic and adipogenic differentiation.  However, lineage tracing 
experiments conducted by Lounev et al. (2009) identified only a small percentage (5%) of 
MyoD-Cre cells within ectopic bone formed by BMP-induced osteogenesis [56].  As well as 
being present on myoblasts, MyoD activation is required for the activation of a population of 
multipotent stem–like cells localised within skeletal muscle, called satellite cells.  These cells 
are crucial for muscle regeneration and repair, and as such, have been implicated in acquired 
HO. 
Satellite Cells 
Satellite cells reside between the sarcolemma and basal lamina of myofibres and are crucial 
for the regeneration of skeletal muscle.  As well as contributing to new myofibre formation, a 
subset of satellite cells is also capable of self-renewal, a defining property of stem cells.  Due 
to this property, satellite cells are often referred to as muscle stem cells.  Much like MSCs, 
previous reports have identified their potential to form myogenic, adipogenic, and osteogenic 
tissue [57].  The fact that muscle contains a unique population of adult stem cells has led to 
them being implicated in ectopic bone formation.  Satellite cells derived from both humans 
and adult mice have been shown to co-express multiple cell fate-determining genes, such as 
the myogenic gene MyoD and the primary regulator of osteogenesis Runx2 [58].  As such, 
these cells are commonly referred to as inducible osteoprogenitors, since their osteogenic 
potential is dependent on the addition of inductive agents such as BMP-2 [59].  Although, 
there is some evidence to suggest that human satellite cells may not require BMP-2 induction 
to reach an osteogenic state [60].  It has been proposed that satellite cells may contribute to 
the formation of ectopic bone as a result of an inability to restrict their phenotypic plasticity 
[58].  One study that isolated rat serum following severe burns (40% total surface area) and 
applied it to satellite cell cultures found enhanced cell proliferation, migration and osteogenic 
differentiation [61].  However, more recent studies suggest that the image of a satellite cell as 
a multipotent cell type capable of contributing to osteochondrogenic differentiation may be 
untrue, with some authors claiming that any non-myogenic differentiation observed in these 
cultures potentially results from contamination with other stem/progenitor cells obtained 
during myofibre isolation [62,63].  In fact, a number of studies can be found that claim  
satellite cells are committed to the myogenic lineage, and as such are crucial for muscle 
regeneration following injury but unlikely to contribute to the formation of ectopic bone seen 
in HO [64,65].   
Mesenchymal Progenitor Cells 
Several progenitor populations, other than satellite cells, have been identified within skeletal 
muscle.  PW1+/Pax7- interstitial cells have recently been identified as a population of non-
satellite myogenic precursors that can adopt a myogenic or vascular fate.  These cells are 
thought to represent a source of postnatal satellite cells, the recruitment of which is dependent 
on the local environment [66].  However, the osteogenic potential of these cells has yet to be 
examined and it remains unknown whether these cells contribute either directly or indirectly 
to HO.  A population of PDGFRα+/Sca-1+ cells have also been localised to the muscle 
interstitium.   These cells have demonstrated both an adipogenic and osteogenic potential, but 
lack the capacity to form skeletal myoblasts [62].  However, due to the fact that 
PDGFRα/Sca-1 positivity is also a defining feature amongst pericytes/pericyte progenitors 
and subsets of bone marrow progenitor cells the exact identity and derivation of these muscle 
progenitors as well as their potential role in HO remains unclear [67].  CD31-/CD45- side 
population cells are a minor subset of MSC-like cells present in uninjured muscle that are 
known to proliferate in response to muscle damage [68].  These cells are thought to 
participate indirectly in muscle regeneration following injury, since they exhibit only a 
limited myogenic differentiation potential in vivo.  These cells have been shown to be capable 
of osteogenic differentiation in vitro but in vivo lineage tracing experiments are required to 
determine the potential role of these cells during HO [69].  Skeletal muscle also contains a 
population of haematopoietic stem cells (HSCs) that have been identified as CD45+/Sca-1+ 
[70].  The osteogenic potential of HSCs isolated from muscle tissue has yet to be studied.  
However, a similar primitive side population of HSCs isolated from the bone marrow was 
shown to be capable of giving rise to osteoblasts through an intermediate mesenchymal phase 
[71].  Studies have indicated that haematopoietic progenitor cells can be split into CD90-
positive and CD90-negative fractions [72].  Both fractions appear capable of osteogenesis; 
however only the CD90-negative fraction has the capacity to form bone containing a central 
bone marrow filled cavity.  These data may imply that the formation of ectopic bone and the 
physiologically accurate endochondral bone found in HO patients have distinct pathologies 
that are linked to similar yet unique cell subsets.  It is also possible that these haematopoietic 
progenitors are related to another cell type implicated in HO, the circulating bone marrow-
derived osteoblast progenitor cells (MOPCs) that have been shown to be mobilised in the 
circulating blood following implantation of BMP-2 [73].  Finally, in a study by Jackson et al. 
(2009) a population of cells termed mesenchymal progenitor cells (MPCs) were isolated from 
traumatised muscle during surgical debridement [34].  This study showed that following 
muscle damage a population of cells could be extracted that exhibited an osteogenic 
differentiation potential comparable to bone marrow-derived mesenchymal stem cells 
(BMSCs).  However, one difference between MPCs and BMSCs was the inability of MPCs 
to reach a terminally differentiated state, as identified by the expression of the end-point 
osteoblast marker osteocalcin (OC) [34].   
 
 
Fig. 2 Based on current evidence, a hypothetical role for cells found within skeletal muscle in the formation of 
ectopic bone. The diagram highlights the potential direct and indirect contribution of well characterised cells 
such as myoblasts and satellite/progenitor cells. It also identifies the potential involvement of under-
characterised resident cells such as muscle interstitium cells and side population MSC-like cells. 
 
Ectoderm 
Epithelial Cells 
Embryonic skeletogenesis is initiated when epidermal cells undergo an epidermal to 
mesenchymal transition.  These mesenchymal cells are then able to differentiate towards 
chondrogenic and osteogenic lineages, in the process of endochondral ossification.  
Currently, the cross-differentiation from cells of one germ layer to another is gaining much 
attention as a process involved in the initiation of HO.  However, the osteogenic potential of 
epithelial cells is subject to much debate, with some studies demonstrating an osteogenic 
potential while others refute it [74, 75].  Early experiments looking into the effects of 
transplanting urinary transitional epithelium into the connective tissues of dogs and rabbits 
demonstrated the formation of mineralised tissue [76], while more recent studies have shown 
that epithelial cells over-express factors required for osteochondrogenic differentiation such 
as TGF-β and BMP-2 during their proliferative phase, and as such may exert a paracrine 
effect during HO pathogenesis [77].  Furthermore, the application of a pulsed electromagnetic 
field (PEMF) has been shown to induce osteogenesis in a population of amniotic epithelial 
cells [78].  This result is particularly interesting given that acquired HO is frequently 
associated with victims of blast injury, and shows that certain populations of epithelial cells 
may have the potential to revert to a mesenchymal phenotype following mechanical stimulus 
[79].  However, more recent data examining the role of epithelial cells in the development of 
HO have shown that these cells are likely to have only a minor and indirect role in HO.  For 
instance, when cultured with mesenchymal cells of the mouse thigh or intramuscularly 
implanted, osteochondrogenic differentiation was observed [74].  However, in this study it 
was not reported whether it was the epithelial cell population or local mesenchymal cells 
within the muscle that contributed to the resultant osteogenic population.  Therefore, to more 
accurately determine whether epithelial cells or mesenchymal cells were responsible for the 
production of ectopic mineral a study was designed in which BMP-7-transduced human oral 
keratinocytes and mesenchymal cells were co-cultured using a diffusion chamber [80].  This 
experimental design allowed the investigators to distinguish whether epithelial cells 
possessed direct osteogenic potential or indirectly affected mesenchymal cells through the 
release of paracrine factors [80].  The results of this experiment confirmed that osteogenic 
material was only formed close to the implanted diffusion chamber on which the 
mesenchymal cells were located, indicating that the mesenchymal cells formed mineral and 
not the epithelial cells.   
Endoderm 
Endothelial Cells 
Recent evidence points to the involvement of endothelial cells in HO.  Tissue vascularisation 
represents a highly important step during the transition from hypertrophic cartilage to bone 
during the endochondral ossification of cartilage growth plates [81].  The formation of neo-
vasculature is also likely to be of key importance for the progression of HO, since the 
formation of bone requires a rich vascular network.  Neo-vascularisation occurs within 
damaged tissue as a result of low oxygen tension produced by local formation of brown 
adipose tissue.  Low oxygen tension leads to the stabilisation of hypoxia-inducible factor-1α 
(HIF-1α), which has been shown to promote transcription of the key vasculogenic factor 
VEGF [42, 82].  Vascularisation is further promoted by hypertrophic chondrocytes located 
within the predominantly avascular cartilage matrix at the onset of endochondral ossification. 
After becoming hypertrophic these cells alter their gene expression profile and produce 
signalling molecules such as VEGF and transferrin that initiate endothelial cell migration 
from the circulation and the accumulation of these cells to the site of calcification [83, 84].   
Endothelial cells have been shown to have a definite indirect contribution to HO, with the 
production of paracrine factors leading to chondrocyte hypertrophy and matrix ossification 
[81].  Recent evidence published by Kim et al. (2013) identified that Ang1/Tie2 signalling in 
MSC cultures led to a strongly osteochondrogenic phenotype, further identifying a link 
between endothelial cells and the pathological process of ectopic bone formation [85].  
Furthermore, there is evidence to indicate that the expression of the endothelial Tie2 receptor 
is increased during osteogenesis and that treatment with angiopoietin 1 (Ang1), a growth 
factor involved in the production of stable vasculature, enhanced osteogenesis by potentiating 
the effects of BMP2 on MSCs [86].  The coupling of angiogenesis and osteogenesis is not a 
newly identified phenomenon, and links between the two processes are found during 
embryogenesis and tissue regeneration [87].  Additionally, much like epithelial cells during 
embryonic skeletogenesis, endothelial cells have been shown to make a transition to a 
mesenchymal cell in a process termed endothelial-mesenchymal transition (EMT) [88].  In 
vivo studies tracing the lineage of osteochondrogenic cells during HO have identified the 
involvement of endothelial cells by the presence of endothelial Tie2-Cre expression on 
chondrocytes and osteoblasts present in the resulting ossified tissue [89].  Further 
investigation identified that endothelial-mesenchymal transition (EMT) could be attributed to 
mutations in ALK2, a type I BMP receptor linked with the development of the hereditary 
condition FOP [89].  The cross-differentiation of endothelial cells to a mesenchymal 
phenotype has been demonstrated by the expression of several identifying surface markers, 
such as Stro-1, CD44, and CD90, among others.  These markers are among several 
distinguishing features of MSCs, potentially indicating that EMT associated with HO results 
in the formation of multipotent stem/progenitor cells that have the capacity to differentiate 
towards an osteochondrogenic cell type.  It would be interesting to further characterise the 
mesenchymal cells formed as a result of EMT to examine their multi-potential.  This would 
help determine whether the mesenchymal cells formed during EMT represented authentic 
MSCs with the potential to form osteogenic, chondrogenic, adipogenic, and potentially 
neurogenic tissues, or more simply a type of endothelial progenitor.  
Further evidence for the potential involvement of endothelial cells in HO is the intermediate 
presence of brown adipose tissue during pathogenesis [42]. Currently, the origin of this 
adipose tissue has yet to be confirmed. A recent study examining the adipogenic potential of 
extracted muscle fibres in vitro found that adipogenic differentiation could only be achieved 
by Tie-2 labelled cells (possible endothelial precursors) present within the heterogeneous 
muscle fibre [65].  This is a highly significant finding given that HO is perhaps most 
commonly observed in skeletal muscle [90].  A derivational link between endothelial cells 
and adipocytes has also been identified, with capillary sprouts present in adipose tissue being 
found to express both endothelial (VE-Cadherin) and pre-adipocyte (Zfp423) markers [91].  
Furthermore, the formation and expansion of adipose tissue is reliant on the presence of a rich 
capillary network.  This data suggests that adipocytes can be of endothelial origin and may 
provide a model for the formation of brown fat during HO [92].  Furthermore, a study by 
Lounev et al. (2009) identified the presence of Tie2-cre labelled cells within ectopic 
osteochondrogenic tissue of HO [56].  Together, this data supports a role for endothelial 
progenitor cells in throughout the fibroproliferative, adipogenic and osteochondrogenic stages 
of HO (see Diagram 3) 
 
Fig. 3 Hypothetical role for resident and vascular endothelial cells in the formation of ectopic bone. The 
diagram highlights the paracrine roles of endothelial cells, as well as the potential direct contribution of these 
cells through endothelial–mesenchymal transition (EMT). Additionally, we would like to propose a potential 
contribution of endothelial cells to the formation of brown adipose tissue during the initial stages of HO. 
 
However, the role of endothelial cells/progenitors was recently called into question following 
the publication of data showing that the Tie2 positive cells found in endochondral bone 
lacked the expression of VE-Cadherin, a principal endothelial marker protein [93].  
Furthermore, Tie2+ cells only accounted for approximately one half of the cells present 
within the ectopic bone mass [56].  Taken together these data allude to the presence of a non-
endothelial Tie2+ VE-Cadherin- cell type.  This data has proven highly interesting given that 
Tie2 is known to be expressed almost exclusively by endothelial cells, quiescent 
haematopoietic stem cells, monocytes and pericytes. Therefore, we suggest that blood vessels 
formed within the developing ectopic bone mass may provide some insight to understanding 
the pathogenesis of HO, but that endothelial cells themselves may not be directly responsible 
for the formation of ectopic bone but rather as a yet unidentified vascular cell type.  
Therefore, the role of cells associated with the vasculature, such as newly discovered 
PDGFRβ+ MSC-like or multipotent cells such as pericytes, needs to be discussed [87].  
Currently, data examining the osteogenic potential of PDGFRβ+ MSC-like cells is lacking.  
These cells have been shown to be associated with a newly discovered and specialised blood 
vessel subtype termed 'type H vessels' that are unique to bone neo-angiogenesis [87].  The 
presence of PDGF receptors as a marker of mesenchymal cells closely associated with the 
vasculature correlates with work conducted by Wosczyna et al. (2012).  This work showed 
that a population of non-endothelial Tie2+ PDGFRα+ Sca-1+ cells in the muscle interstitium 
was found to be consistently incorporated into chondrogenic and osteogenic lesions [94].  
However, the expression of PDGFα also draws a direct comparison with bone marrow-
derived pericyte progenitors (PDGFRα+ Sca-1+) previously identified by Uezumi et al. (2010) 
[62] (see Table 1).  What is most interesting about these reports is that both PDGFR and Sca-
1 are defined as MSC/progenitor cell markers [95].  This suggests that the cells responsible 
for HO may be associated with the vasculature but mesenchymal in origin.   
Neural Crest 
Pericytes 
Pericytes are contractile cells that envelope the surface of the vascular wall of blood vessels, 
where they communicate with endothelial cells.  These cells have been defined as PDGFRβ+, 
and therefore could be linked with the population of MSC-like cells found in blood vessels 
[67,87].  However, confusion regarding the identity, progeny and ontogeny of pericytes 
abounds, and the relationship between these cells and other mesenchymal cells such as MSCs 
and vascular smooth muscle cells (vSMCs) remains elusive [96].  Pericytes have been shown 
to have an osteogenic potential when cultured both in vitro and in vivo, and consequently 
could be implicated in HO [97].  In fact, conjecture relating to the aberrant differentiation of 
pericytes along osteogenic, chondrogenic and adipogenic lineages has implicated these cells 
in a number of similar pathological conditions, such as atherosclerosis and ectopic 
calcification [98].  One current opinion is that pericytes are in fact multipotent cells capable 
of forming fat, cartilage and bone, but that these differentiation pathways are repressed 
except in cases of pathogenesis [96].  For example, a study by Kirton et al. (2007) has shown 
that the chondrogenic differentiation pathway of pericytes can be activated by Wnt/beta-
catenin signalling in the presence of TGF-β3 [98].  Additionally, a recent study by Kan et al. 
(2013) identified that cells presenting the glutamate transporter GLAST were found to 
contribute to the formation of ectopic bone, and that these GLAST+ cells appeared to be 
distinct from the Tie2+ population identified by Woscyzna et al. (2012) [94]. Pericyte 
populations have been shown to express GLAST [99], and consequently this information 
further highlighted the potential role of these cells during HO.  However, due to a lack of 
novel surface markers that can be used for the definitive phenotypic characterisation of 
pericytes in vivo, the role of these cells in HO remains elusive.  For instance a study 
presented by Armulik et al. (2011) identified pericytes based on the positive expression of α-
smooth muscle actin (α-SMA) and a lack of expression of the endothelial marker von 
Willebrand factor (vWF) [100].  However, this method of identification fails to provide a 
means of distinguishing between pericytes, vascular smooth muscle cells, myofibroblasts and 
MSCs, which are all α-SMA+ vWF- [101].  Furthermore, the fact that purified perivascular 
cells exhibit multipotency and become indistinguishable from traditional MSCs when 
expanded in culture has fuelled continued debate over the relationship between pericytes and 
MSCs [96].  However, due to a lack of unique cell surface markers, limitations exist 
concerning the phenotypic characterisation of these cells in vivo, and the precise relationship 
between these cells and MSCs remains elusive.  Therefore, further in vivo cell tracking 
experiments are required that accurately identify pericytes based on an established 
CD146+/CD34- phenotype in order to determine the contribution of these cells to the ectopic 
bone mass [96].   
Pericyte Progenitor Cells 
It is interesting to note that at least three populations of bone marrow-derived cells are known 
to give rise to pericytes [67].  For instance studies have identified bone marrow-derived 
PDGFR-β+/Sca-1+/CD11b+ pericyte progenitors [102], bone marrow-derived CD45+/CD11b+ 
progenitors [103], and Sca-1+/Tie2+/CD13+ pericyte progenitors that have been associated 
with tumour development [104].  To our knowledge, there is no information on the 
osteochondrogenic capacity of these cells and as such their potential roles during HO remains 
unknown.  However, based on knowledge of the phenotypic profile of these cells and the 
osteochondrogenic potential of mature pericytes, it could be postulated that the Tie2+ cells 
identified in endochondral bone by Lounev et al. (2009) represent a population of pericyte 
progenitors rather than endothelial cells, as first proposed [56].  This hypothesis would 
account for the fact that the cell population identified within ectopic bone by Lounev et al. 
(2009) was Tie2+ but lacked the expression of VE-Cadherin, a principal endothelial marker 
[56].  Furthermore, the fact that pericyte progenitors are a heterogeneous population with 
differing immunophenotypes could account for the fact that only approximately 60% of the 
cells found in endochondral bone were Tie2+ [56].  Therefore, we identify the need for 
further studies to determine the presence of other common markers of pericyte progenitor 
cells such as Sca-1.   
 
 
 
 
 
 
Cell Type Immunophenotype Chondrogenic Osteogenic  References 
MSC CD73
+/CD90+/ 
CD105+ Y Y 28, 29, 30 
Myoblast MyoD+/Myf5+ N Y 46, 49, 50, 51, 52, 55 
Satellite Cell Pax7+/Sca-1+/CD34+ Y/N Y/N 57, 60, 65 
Interstitial Cell PW1+/Pax7- ? ? 66 
Interstitial Cell PDGFRα+/Sca-1+ ? Y 62, 94 
Muscle Side 
Population Cells CD31
-/CD45- ? Y 68, 70 
Muscle 
Haematopoietic 
Stem Cells (HSC) 
CD45+/Sca-1+ ? ? 70 
Bone Marrow HSC 
Side Population Lin
-/Sca-1+/cKit+/CD45+ ? Y 71 
Circulating 
Osteogenic 
Precursor (MOPC) 
CD44+/CXCR4+/SDF-1+ ? Y 73 
Mesenchymal 
Precursor Cell 
(MPC) 
CD44+/CD49e+/CD73+/CD90+/C
D105+ Y Y 34 
Pericyte CD146
+/α-SMA+, vWF-
/PDGFRβ+ 
Y Y 94, 97, 98 
Bone Marrow-
Derived Pericyte 
Progenitors 
 
PDGFRβ+/Sca-1+/CD11b+  
 
CD45+/CD11b+  
 
Sca-1+/Tie2+/CD13+ 
 
? ? 102, 103, 104 
Epithelial Cells E-Cadherin+/KL1+/EpCAM+ Y/N Y/N 76, 77, 78, 79 
Endothelial Cells Tie2+/VE-Cadherin+ Y Y 89 
PDGFβ+ MSC-like 
Cells PDGFβ
+ ? ? 87, 89 
The table shows the immunophenotype of these cells as well as their ability to differentiate towards 
chondrogenic and osteogenic lineages, as would be required for endochondral ossification 
 
Abbreviations 50-Nucleotidase (CD73), Thymocyte antigen 1 (CD90), endoglin (CD105), myogenic 
differentiation 1 (MyoD), myogenic factor 5 (Myf5), paternally expressed gene 3 (PW1/Peg3), paired box 
protein 7 (Pax7), stem cell antigen-1 (Sca-1), hematopoietic progenitor cell antigen (CD34), platelet-derived 
growth factor receptor alpha (PDGFRa), platelet endothelial cell adhesion molecule (CD31/PECAM-1), 
leukocyte common antigen (CD45/LCA), lineage cocktail (Lin), mast/stem cell growth factor receptor (cKit), 
homing cell adhesion molecule (CD44), integrin alpha-2 (CD49e), melanoma Cell adhesion molecule 
(CD146/MCAM), C-X-C chemokine receptor type 4 (CXCR4), stromal cell-derived factor 1 (SDF-1), alpha 
smooth muscle actin (a-SMA), von Willebrand Factor (vWF), Integrin Alpha M (CD11b/ITGAM), Tie receptor 
tyrosine kinase (Tie2), Aminopeptidase N (CD13), epithelial cadherin (E-cadherin), Cytokeratin 1 (KL1), 
Epithelial cell adhesion molecule (EpCAM), vascular endothelial cadherin (VE-Cadherin), Platelet-derived 
growth factor beta (PDGFb). Italics denote other commonly used abbreviations for each marker. 
 
Future Treatment Strategies  
Prediction and Diagnosis 
Significant benefits may be gained by early identification of patients who will go on to 
develop HO. Reliable risk stratification and prediction allows clinicians to target prophylactic 
therapies at the right patients, thus reducing the risk of harmful side effects in those who are 
not at risk of developing HO. Several techniques are being developed to achieve this goal. In 
one example, the risk of a patient developing HO is identified by measuring key local and 
systemic inflammatory biomarkers at the time of first surgical debridement [26]. However, it 
must be noted that these studies have not been validated in a civilian population and the 
authors’ stress that the complex interrelationship between the inflammatory markers remains 
incompletely understood.  The same group has also looked upstream at osteogenic gene 
expression as a predictor of HO in combat wounds [105]. They report a significant 
upregulation in transcriptional activity in key osteogenesis-related genes (ALPL, BMP-2, 
BMP-3, COL2A1, COLL10A1, COL11A1, COMP, CSF2, CSF3, MMP8, MMP9, SMAD1, 
VEGFA) in patients that developed HO compared to those who did not. This study may, 
however, be confounded by the finding that the HO group had a significantly higher injury 
burden, more bacterial colonisation, bigger wounds, and more amputations than the non-HO 
group. 
The predictive ability of advanced non-invasive imaging techniques has also been the subject 
of recent research activity. In vivo Raman spectroscopy has been employed to detect bone 
mineral deposition in a rodent HO model as soon as 5 days post injury [106]. In a similar 
manner, the same group have developed a near infra-red optical imaging system that can 
demonstrate HO formation 5 days after injury [107]. Not only are these techniques able to 
detect HO sooner after injury than any other modality but they are non-invasive and do not 
rely on ionising radiation.  
Treatment 
In order to exploit earlier diagnosis, novel anti-HO treatments are being developed. One 
strategy that has shown great promise is retinoic acid receptor gamma (RARγ) agonism to 
inhibit chondrogenesis [108]. Without a cartilage scaffold, the endochondral processes that 
form HO are blocked and no mineral can be deposited. It is worth noting that, in the rodent 
model, there was a transient prolongation of fracture healing associated with RARγ agonism. 
However, the mechanism was so effective that the RARγ agonist Palovarotene has been taken 
forward into clinical trials (NCT02279095) as a treatment for the genetic form of HO known 
as fibrodysplasia ossificans progressive (FOP) [109]. 
Another novel strategy has been demonstrated in a burn-tenotomy rodent HO model [37] 
whereby hydrolysis of ATP at the burn site lead to reduced HO formation at a distant site. In 
addition to revealing a potential therapeutic strategy, this “remote ATP hydrolysis” method 
provides a further mechanistic insight into the role of phosphorylated SMAD proteins in the 
development of HO. In another rodent tenotomy model (without burn injury), treatment with 
the antibiotic echinomycin inhibited HO formation [110]. The proposed mechanism is that 
echinomycin inhibits hypoxia-induced factor 1-α (HIF-1-α), a signalling molecule thought to 
be crucial to the process of chondrogenic differentiation of mesenchymal stem cells in HO. 
Heterotopic ossification research has diversified massively in the last few years. Rather than 
simply optimising the well-understood treatment modalities, researchers are exploiting 
breakthroughs in the understanding of the pathogenesis of this condition to diagnose it earlier 
and develop completely novel therapeutic strategies.  However, a better understanding of the 
cellular and molecular mechanisms leading to HO is required for the development of novel 
therapeutics. 
Conclusion 
HO is likely to result from a highly complex interplay between a number of cell types that are 
either resident in the damaged tissue or recruited from the circulation following trauma and 
inflammation.  The majority of current evidence practically excludes cells of ectodermal 
origin as primary contributors to HO, however the paracrine effects of these cells cannot be 
ruled out.  Perhaps the most promising evidence so far links the onset of HO with the release 
of pro-angiogenic factors following injury, and therapies that utilise anti-angiogenic 
molecules may be significant for the prevention of HO.  This review identifies a potential role 
of endothelial cells during the onset of HO but concludes that non-endothelial cells closely 
associated with the vasculature, such as pericytes or multipotent cells of mesenchymal origin 
are likely to be directly involved in the pathogenesis.  Throughout this review, we have 
identified that limitations in phenotyping, and overlap between the identities of different 
populations of mesenchymal progenitors/stem cells limit the power of current in vivo 
methods.  In fact, the lack of unique sets of cell surface markers together with significant 
overlap and confusion regarding the relationships between different subsets of 
stem/progenitor cells is perhaps one of the fundamental issues delaying progress in HO 
research.  Therefore, the need for a more comprehensive understanding of stem/progenitor 
subpopulations, and the hierarchies that exist between them, is required before HO 
contributors can be accurately identified.  
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Table and Figures 
Table 1. 
Comprehensive list of cells potentially involved in HO.  The table shows the 
immunophenotype of these cells as well as their ability to differentiate towards chondrogenic 
and osteogenic lineages, as would be required for endochondral ossification. Abbreviations: 
5’-Nucleotidase (CD73), Thymocyte antigen 1 (CD90), Endoglin (CD105), Myogenic 
differentiation 1 (MyoD), Myogenic factor 5 (Myf5), Paternally expressed gene 3 
(PW1/Peg3), Paired box protein 7 (Pax7), Stem cell antigen-1 (Sca-1), Hematopoietic 
progenitor cell antigen (CD34), Platelet-Derived Growth Factor Receptor alpha (PDGFRα), 
Platelet Endothelial Cell Adhesion Molecule (CD31/PECAM-1), Leukocyte Common 
Antigen (CD45/LCA), Lineage cocktail (Lin), Mast/Stem cell growth factor receptor (cKit), 
Homing cell adhesion molecule (CD44), Integrin alpha-2 (CD49e), Melanoma Cell Adhesion 
Molecule (CD146/MCAM), C-X-C chemokine receptor type 4 (CXCR4), Stromal Cell-
Derived Factor 1 (SDF-1), Alpha Smooth Muscle Actin (α-SMA), von Willebrand Factor 
(vWF), Integrin Alpha M (CD11b/ITGAM), Tie receptor tyrosine kinase (Tie2), 
Aminopeptidase N (CD13), Epitheial Cadherin (E-Cadherin), Cytokeratin 1 (KL1), Epithelial 
Cell Adhesion Molecule (EpCAM), Vascular Endothelial Cadherin (VE-Cadherin), Platelet-
Derived Growth Factor Beta (PDGFβ). Italics denote other commonly used abbreviations for 
each marker. 
Diagram 1.  
Hypothetical mechanism for the pathological changes associated with the development of HO 
following trauma.  Tissue damage leads to the infiltration of immunological cells (monocytes, 
neutrophils, leukocytes) through the local vasculature.  Resulting fibro-proliferation of an as 
yet unknown cell population is accompanied by hypoxia and the generation of brown adipose 
tissue at the site of damage.  The presence of adipose tissue is hypothesised to lower the local 
oxygen tension leading to the establishment of a chondrogenic environment.  
Neovascularisation accompanies chondrogenesis and provides an avenue through which 
systemic cell types (endothelial cells, pericytes etc.) may enter the injury site, and potentially 
contributed to osteochondrogenic differentiation.  A subsequent increase in local oxygen 
tension promotes chondrocyte maturation and hypertrophy.  The collagenous matrix 
deposited by these cells is then remodelled and ossified to form endochondral bone. 
Diagram 2. 
Based on current evidence, a hypothetical role for cells found within skeletal muscle in the 
formation of ectopic bone.  The diagram highlights the potential direct and indirect 
contribution of well characterised cells such as myoblasts and satellite/progenitor cells.  It 
also identifies the potential involvement of under-characterised resident cells such as muscle 
interstitium cells and side-population MSC-like cells. 
Diagram 3. 
Hypothetical role for resident and vascular endothelial cells in the formation of ectopic bone.  
The diagram highlights the paracrine roles of endothelial cells, as well as the potential direct 
contribution of these cells through endothelial-mesenchymal transition (EMT).  Additionally, 
we would like to propose a potential contribution of endothelial cells to the formation of 
brown adipose tissue during the initial stages of HO. 
 
 
